In pediatric medicine, BET inhibitors are gaining attention due to their potential role in treating pediatric cancers and other diseases. Children's cancers often have distinct molecular profiles compared to adult cancers, necessitating tailored therapeutic approaches. BET inhibitors, by modulating gene expression, offer a novel therapeutic strategy that could be beneficial in treating aggressive or treatment-resistant pediatric tumors.
